P-gp has been implicated in cellular resistance to anticancer drugs, which is believed to be originated in a lowering of the concentration of many anticancer drugs in tumor cells, although the level of the diminution due to the P-gp action itself remains unclear [3–5]. The gene discussed is PGP; the disease is neoplasm.